Antipsychotic dosing: extended, and transient.

@article{Seeman2012AntipsychoticDE,
  title={Antipsychotic dosing: extended, and transient.},
  author={P. Seeman and G. Remington},
  journal={Clinical schizophrenia & related psychoses},
  year={2012},
  volume={6 2},
  pages={
          86-7
        }
}
  • P. Seeman, G. Remington
  • Published 2012
  • Medicine
  • Clinical schizophrenia & related psychoses
  • New Ways of Antipsychotic Dosing Considering the few new medications being developed for schizophrenia, it is recognized that novel avenues of research are needed for drug treatment of schizophrenia. While current antipsychotic drugs primarily block dopamine D2 receptors or interfere with dopamine neurotransmission (1, 2), many drugs for non-D2 pathways and receptors have been tested as possible antipsychotics, but not with much success. These include antagonists or agonists at receptors for D1… CONTINUE READING
    1 Citations
    Investigational drugs for schizophrenia targeting the dopamine receptor: Phase II trials
    • 11

    References

    SHOWING 1-10 OF 15 REFERENCES
    Dopamine D2 receptors as treatment targets in schizophrenia.
    • P. Seeman
    • Medicine
    • Clinical schizophrenia & related psychoses
    • 2010
    • 152
    Brain receptors for antipsychotic drugs and dopamine: direct binding assays.
    • 652
    • PDF